Alx oncology announces upcoming investor conference participation

South san francisco, calif., sept. 01, 2022 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo) a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences.
ALXO Ratings Summary
ALXO Quant Ranking